2024
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohort
2016
Assessing the utility of Xpert® MTB/RIF as a screening tool for patients admitted to medical wards in South Africa
Heidebrecht CL, Podewils LJ, Pym AS, Cohen T, Mthiyane T, Wilson D. Assessing the utility of Xpert® MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. Scientific Reports 2016, 6: 19391. PMID: 26786396, PMCID: PMC4726405, DOI: 10.1038/srep19391.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCoinfectionDrug Resistance, BacterialFemaleHIV InfectionsHumansMaleMass ScreeningMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisNucleic Acid Amplification TechniquesReproducibility of ResultsRifampinSouth AfricaTuberculosis, Multidrug-ResistantYoung AdultConceptsChest X-rayMTB/RIFMedical wardsScreening toolAdditional TB casesInfection control actionsUtility of GeneXpertTB/HIVConsecutive adult patientsProportion of patientsRifampicin-resistant tuberculosisDrug-resistant tuberculosisLarge public hospitalTB diseaseAdult patientsStandard careTB casesTB screeningMedical admissionsMedical chartsHospital inpatientsSputum specimensGeneXpertPatientsRifampicin resistance
2006
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations
Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7042-7047. PMID: 16632605, PMCID: PMC1459015, DOI: 10.1073/pnas.0600349103.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyDrug-resistant TBCommunity-wide isoniazid preventive therapyPreventive therapyTuberculosis infectionTB controlLatent Mycobacterium tuberculosis infectionLatent tuberculosis infectionProportion of patientsMycobacterium tuberculosis infectionIncidence of TBTuberculosis case notificationCommunity-wide implementationEmergence of HIVCommunity-wide strategiesHIV-tuberculosisTB-HIVCoinfected individualsTB epidemicCase notificationTreatment policyHIVTherapyInfectionTB